Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Kansas City Veteran Affairs Medical Center |
---|---|
Information provided by: | Kansas City Veteran Affairs Medical Center |
ClinicalTrials.gov Identifier: | NCT00728520 |
The drug that will be used in this study is called Azacitidine. Azacitidine belongs to a group of drugs which may restore normal control in cancer cells by affecting the genes and proteins in the body. Azacitidine is approved by the FDA for the treatment of Myelodysplastic Syndrome (MDS), a pre-leukemic bone marrow disease. The purpose of this study is to find out what effect the drug Azacitidine has on Acute Myeloid Leukemia (AML) in elderly patients.
Condition | Intervention | Phase |
---|---|---|
Acute Myeloid Leukemia Elderly |
Drug: Azacitidine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study |
Estimated Enrollment: | 40 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | June 2012 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Prior to starting treatment individuals being considered for this study will be evaluated to determine if they are eligible to participate in the study. There are certain prestudy test that are required: physical exam, blood tests, ECG, chest x-ray, bone marrow aspirate and biopsy to confirm the diagnosis of AML.
Treatment regimen consists of Azacitidine IV/SQ on days 1-5 every 28 days. If the Azacitidine is given IV it will be given over 15-40 minutes. The treatment will be given for a minimum of 4 treatment cycles. Blood samples will be taken every week to monitor for side effects of the Azacitidine. A bone marrow aspirate will be done every 3-4 months to determine the response to the study drug or until the disease progresses. There is also a quality of life questionnaire that will be completed at the beginning of the study and every 4 weeks while on the study.
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sarah Spencer, RN, BSN | 816-861-4700 ext 57665 | sarah.spencer@va.gov |
Contact: Suman Kambhampati, MD | 816-861-4700 | suman.kambhampati@va.gov |
United States, Missouri | |
Kansas City Veterans Affairs Medical Center | Recruiting |
Kansas City, Missouri, United States, 64218 | |
Contact: Sarah E Spencer, RN, BSN 816-861-4700 ext 57665 sarah.spencer@va.gov | |
Contact: Suman Kambhampati, MD 816-861-4700 ext 57075 suman.kambhampati@va.gov | |
Principal Investigator: Suman Kambhampati, MD | |
Sub-Investigator: Peter J. Van Veldhuizen, MD | |
Sub-Investigator: Chao H. Huang, MD | |
Sub-Investigator: Chester Stone, MD |
Principal Investigator: | Amit Verma, MD | Albert Einstein College of Medicine of Yeshiva University |
Responsible Party: | Kansas City Veterans Affairs Medical Center ( Suman Kambhampati, MD ) |
Study ID Numbers: | SK0010 |
Study First Received: | July 31, 2008 |
Last Updated: | August 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00728520 |
Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
Leukemia Azacitidine Untreated Elderly |
Leukemia Azacitidine Acute myelogenous leukemia |
Leukemia, Myeloid Leukemia, Myeloid, Acute Acute myelocytic leukemia |
Antimetabolites Neoplasms Antimetabolites, Antineoplastic Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Pharmacologic Actions |